Open company graph database — free web & API
Login

Oil Japan Agro Research Co., Ltd.

油日アグロリサーチ株式会社
Ticker
—
Listed market
—
Country
Japan
Employees (consolidated)
41
Related companies
2
§01

Basic information

BASIC
Head office
1405 Gotanda, Koka Town, Koka City, Shiga Prefecture
Chief executive
Eisaku Nanohana
Capital
10,000,000 JPY
Employees (non-consolidated)
Employees (consolidated)
41 people
Start date
2004-02-26
End date
§02

Websites

1 DOMAINS
§03

Business

3
Contract testing of pesticidesManagement of botanical gardensGreening management of owned land
§04

Related companies

2 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Shionogi & Co., Ltd.
Group
SHIONOGI Group Worldwide
Group
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

65 EVENTS

Founder Yoshisaburo Shio no established Shio no Yoshisaburo Store in Doushū-cho, Osaka, selling traditional and Western medicines.Sources

Shionogi Yoshimasa founded the drug wholesaler 'Shionogi Yoshimasa Shop' on March 17, 1878, at 3-12 Motosho-cho, Osaka.Sources

Converted product line to Western medicines.Sources

In 1886, with the spread of Western medicine, began importing and selling Western drugs.Sources

Started direct transactions with Western trading companies.Sources

Manufactured and sold in-house new drug No.1 antacid 'Antachijin'; trademark registered with the 'Bento' mark.Sources

Yoshimasa's second son, Nagajiro, began trial production of an antacid and succeeded in commercializing it. This became the company's first self-developed new drug 'Antachijin'.Sources

Shionogi Shop registered the Balance Mark, symbolizing accuracy and reliability, as a trademark.Sources

Constructed Shio Pharmaceutical Plant in Fukushima-ku, Osaka City.Sources

Yoshimasa built the Shionogi Pharmaceutical Plant in Nishinari-ku, Osaka Prefecture, and began full operations in 1910.Sources

Introduced by the plant director, Kondo Heisaburo, the new cardiac drug 'Digitamin' was launched.Sources

Merged Shio Yoshisaburo Store and Shio Pharmaceutical Plant, reorganized into Shio Yoshishō Store Co., Ltd.Sources

In 1943, after the war, changed the company name to Shionogi Pharmaceutical Co., Ltd.Sources

Established Kase Factory in Amagasaki, Hyogo Prefecture (now Kase Office); set up a laboratory inside the factory.Sources

Built new headquarters building in Doushū-cho, Osaka City.Sources

Changed company name to Shio Yoshishō Pharmaceutical Co., Ltd.Sources

In 1945, after the war, the drug wholesaler Shionogi Yoshimasa Shop and the pharmaceutical business Shionogi Pharmaceutical Plant merged to form 'Shionogi Yoshimasa Shop Co., Ltd.'.Sources

Established Oil Japan Farm in Shiga Prefecture (now Oil Japan Office).Sources

In response to the post-war management crisis, Yoshimasa implemented management improvement measures such as technology upgrades and cost reductions, advancing rationalization.Sources

Listed on stock exchanges in Tokyo and Osaka.Sources

Released painkiller 'Sedes'.Sources

The analgesic 'Sedex' was launched in 1950.Sources

Released comprehensive vitamin supplement 'Popon S'.Sources

After the name change in 1943, it officially became 'Shionogi Pharmaceutical Co., Ltd.' in 1953.Sources

Established basic policy.Sources

Since its founding, the company has continued to emphasize producing better products, accurate sales, and technological advancement as part of its corporate culture.Sources

Discovery of Shinomin; established the Detailman system.Sources

Released sulfa drug 'Shinomin'.Sources

Constructed Central Research Institute in Fukushima-ku, Osaka City (now consolidated into the Pharmaceutical Research Center).Sources

Established the Animal Pharmaceutical Department (transferred in 2002), established the Plant Pharmaceutical Department (transferred in 2001), commenced operations of the Clinical Laboratory (transferred in 2002): Established Shionogi Taiwan Pharmaceutical Co., Ltd.Sources

Broadcast of the program 'Shionogi Music Fair' provided by a single company commenced.Sources

Construction of Settsu Factory (Settsu City, Osaka Prefecture).Sources

Established Nippon Asia Pharmaceutical Industry Co., Ltd. (now Shionogi Pharma Co., Ltd.).Sources

Construction of Shionogi Shibuya Building (Shibuya-ku, Tokyo): Construction of New Drug Research Institute (Toyonaka City, Osaka Prefecture) (now Pharmaceutical Research Center).Sources

Release of oxacillin-type antibiotic 'Shiomarin'.Sources

Construction of Kanegasaki Factory (Iwate Prefecture).Sources

Construction of Medical Science Research Institute (within Settsu Factory site) (now consolidated into Pharmaceutical Research Center): Release of oxacillin-type antibiotic 'Furamarin'.Sources

Established Shionogi General Service Co., Ltd. (now Shionogi Business Partner Co., Ltd.): Acquired capsule business from Eli Lilly (sold in 2005).Sources

Construction of New Headquarters Building (Michi-shu-cho, Osaka City).Sources

Release of cephalosporin antibiotic 'Frolomax'.Sources

Establishment of Shionogi Code of Conduct (revised 2012): Founded Oomori Pharmaceutical Co., Ltd. (sold in 2002): Established Musshu Pharmaceutical Co., Ltd. (sold in 2010).Sources

Start of First Medium-Term Management Plan.Sources

To focus on the pharmaceutical business, the company transferred plant medicines, animal medicines, and pharmaceutical wholesale to other companies, accelerating research and development and advancing overseas expansion.Sources

Established Shionogi USA, Inc. (now Shionogi Inc.): Overseas JV: Established Shionogi-GlaxoSmithKline Pharmaceuticals LLC (later Shionogi-ViiV Healthcare LLC) and began joint research and development of HIV treatment drugs.Sources

Release of cancer pain treatment drug 'Oxycontin'.Sources

Start of Second Medium-Term Management Plan: Release of high cholesterol treatment drug 'Crestol': Release of carbapenem antibiotic 'Finibax'.Sources

A development subsidiary was established in the United States, and a joint drug development program was launched with GlaxoSmithKline in the United Kingdom.Sources

Established Shionogi Analytical Center Co., Ltd.: Release of cancer pain treatment granule 'Okinome'.Sources

Acquired US-based Sciele Pharma, Inc. (now Shionogi Inc.): Established joint research facility with Hokkaido University, Shionogi Drug Innovation Center: Release of hypertension treatment drug 'Ilbetan': Release of acne treatment drug 'Defirin': Release of idiopathic pulmonary fibrosis treatment drug 'Pirespa'.Sources

Start of Third Medium-Term Management Plan: Established Shionogi Techno Advance Research Co., Ltd.: Established Osaka University Graduate School of Medicine-affiliated PET Molecular Imaging Center: Release of anti-influenza virus drug 'Rapiacta': Release of antidepressant 'Sainbarta'.Sources

Acquired Chinese pharmaceutical company C&O Pharmaceutical Technology (Holdings) Ltd.: Constructed new building SPRC4 within the Pharmaceutical Research Center (SPRC) and consolidated drug discovery research functions.Sources

The company acquired the Chinese pharmaceutical company C&O Pharmaceutical Technology (Holdings) Limited.Sources

Established European subsidiary Shionogi Limited (UK) : Signed a new framework agreement with Vibe Healthcare regarding HIV treatment drugs : Launched cancer pain treatment injectable 'Oxfast' : Launched hypertension drug 'Aimix'.Sources

Shionogi Limited was established in the United Kingdom, promoting globalization.Sources

Established Beijing Shionogi Pharmaceutical Technology Co., Ltd. (China) : Established Shionogi Singapore Pte. Ltd. : Modified royalty agreement for Crestol with AstraZeneca : Launched postmenopausal vaginal atrophy drug 'Osphena' in the United States : Launched hypertension drug 'Iltra'.Sources

Launched mid-term management plan 'Shionogi Growth Strategy 2020 (SGS2020)' : Launched HIV treatment drug 'Tebikei'.Sources

Aiming for growth as a drug discovery-based pharmaceutical company, a medium-term management plan based on ROE was formulated, advancing flexible business development responsive to environmental changes.Sources

Launched HIV treatment drug 'Triemek' : Launched allergen immunotherapy drug 'Asitia' : Launched thrombocytopenia treatment drug 'Mulpreta'.Sources

Updated mid-term management plan 'SGS2020' : Established Shionogi Healthcare Co., Ltd. : Launched high cholesterol drug 'Crestol OD tablets'.Sources

Established domestic group companies: Shionogi Career Development Center Co., Ltd., Shionogi Digital Science Co., Ltd., Shionogi Business Partner Co., Ltd., Shionogi Pharma Pharmacovigilance Center Co., Ltd., Shionogi Marketing Solutions Co., Ltd. : Launched cancer pain treatment drug 'Mesapain' : Launched ADHD treatment drug 'Inchunib' : Launched opioid-induced constipation treatment drug 'Symproic' in the United States : Launched opioid-induced constipation treatment drug 'Soinproik' : Launched sustained cancer pain treatment drug 'Oxycontin TR tablets'.Sources

Established Shionogi Pharma Co., Ltd. : Established European subsidiary Shionogi B.V. : Launched anti-influenza drug 'Zoflura' : Launched thrombocytopenia treatment drug 'Mulpleta' in the United States : Launched anti-HIV drug 'Jaruka'.Sources

Established joint venture 'Stream-I Co., Ltd.' with M3 : Consolidated UMN Pharma Co., Ltd. as a subsidiary : Opened Shionogi Education and Training Center in Amagasaki City : Launched opioid-induced constipation treatment drug 'Rizmoic' in Europe : Launched anti-influenza drug 'Shufukou' in Taiwan : Launched ADHD treatment drug 'Vivance'.Sources

Launched mid-term management plan 'Shionogi Transformation Strategy 2030 (STS2030)' : Established joint venture 'Ping An Shionogi Co., Ltd.' with Ping An Insurance : Fully acquired Tetra Corp. in the United States : Acquired Nagase Pharmaceutical as a subsidiary through Shionogi Pharma : Launched gram-negative bacterial infection drug 'Fetroja' in the United States : Launched gram-negative bacterial infection drug 'Fetcroja' in Europe.Sources

Launched wastewater epidemiology service for COVID-19 : Launched opioid-induced constipation treatment drug 'Soinproik' in Taiwan.Sources

Established joint venture 'AdvanSentinel Co., Ltd.' with Shimadzu Corporation : Established General Foundation 'Shionogi Infectious Disease Research Promotion Foundation' : Built SHIONOGI Group brand and established group brand mark : Established Yui Connection Co., Ltd. : Launched COVID-19 treatment drug 'Zokova'.Sources

§07

News

0 ARTICLES

There is no news.

§08

Public records

GOV
National Tax Agency basic information2160001005740
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
油日アグロリサーチ株式会社
Trade name (kana)
アブラヒアグロリサーチ
Name in English
Corporation type
301
Address
〒520-3423 滋賀県甲賀市甲賀町五反田1405番地
Postal code
5203423
Prefecture code
25
City code
209
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2018-06-28
Change date
2015-10-05
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
01
Correction type
1
Trade name image ID
Address image ID
Sequence number
3830871
METI gBizINFO2160001005740
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
2160001005740
Trade name
油日アグロリサーチ株式会社
Trade name (kana)
アブラヒアグロリサーチ
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
滋賀県甲賀市甲賀町五反田1405番地
Postal code
5203423
Prefecture
滋賀県
Prefecture code
25
City or district
甲賀市
City code
209
Street address
甲賀町五反田1405番地
Organisation type
301
Processing type
01
Correction type
1
Status
Representative
Capital
Employees
Employees (male)
Employees (female)
Business summary
Website URL
Year founded
Business category
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date
2018-06-28
Key information
2160001005740
§09

Sources & updates

SOURCES
↑